Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment

por Zhu, Winston M, Middleton, Mark R
Publicado 2023

Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis

por Findlay, John M., Middleton, Mark R., Tomlinson, Ian
Publicado 2015

Erratum to: Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis

por Findlay, John M., Middleton, Mark R., Tomlinson, Ian
Publicado 2016

Genetic susceptibility to Barrett’s oesophagus: Lessons from early studies

por Findlay, John M, Middleton, Mark R, Tomlinson, Ian
Publicado 2015

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report

por Dooley, Andrew J., Gupta, Avinash, Middleton, Mark R.
Publicado 2016

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

por Toor, Kabirraaj, Middleton, Mark R., Chan, Keith, Amadi, Adenike, Moshyk, Andriy, Kotapati, Srividya
Publicado 2021

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

por Morrell, Liz, Wordsworth, Sarah, Schuh, Anna, Middleton, Mark R., Rees, Sian, Barker, Richard W.
Publicado 2018

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

por Morrell, Liz, Wordsworth, Sarah, Schuh, Anna, Middleton, Mark R., Rees, Sian, Barker, Richard W.
Publicado 2019

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

por Middleton, Mark R., Hoeller, Christoph, Michielin, Olivier, Robert, Caroline, Caramella, Caroline, Öhrling, Katarina, Hauschild, Axel
Publicado 2020

Societal preferences for adjuvant melanoma health states: UK and Australia

por Middleton, Mark R., Atkins, Michael B., Amos, Kaitlan, Wang, Peter Feng, Kotapati, Srividya, Sabater, Javier, Beusterien, Kathleen
Publicado 2017

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

por Andtbacka, Robert H. I., Collichio, Frances, Harrington, Kevin J., Middleton, Mark R., Downey, Gerald, Ӧhrling, Katarina, Kaufman, Howard L.
Publicado 2019

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes

por de Santiago, Ines, Yau, Christopher, Heij, Lara, Middleton, Mark R., Markowetz, Florian, Grabsch, Heike I., Dustin, Michael L., Sivakumar, Shivan
Publicado 2019

Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence

por Findlay, John M., Dickson, Edward, Fiorani, Cristina, Bradley, Kevin M., Mukherjee, Somnath, Gillies, Richard S., Maynard, Nicholas D., Middleton, Mark R.
Publicado 2019

Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultr...

por Lyon, Paul C., Griffiths, Lucy F., Lee, Jenni, Chung, Daniel, Carlisle, Robert, Wu, Feng, Middleton, Mark R., Gleeson, Fergus V., Coussios, Constantin C.
Publicado 2017

Routinely staging gastric cancer with (18)F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery

por Findlay, John M., Antonowicz, Stefan, Segaran, Ashvina, el Kafsi, Jihene, Zhang, Alexa, Bradley, Kevin M., Gillies, Richard S., Maynard, Nicholas D., Middleton, Mark R.
Publicado 2019

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

por Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth
Publicado 2021

Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials

por Malczewski, Agnieszka, Marshall, Andrea, Payne, Miranda J., Mao, Lili, Bafaloukos, Dimitrios, Si, Lu, Pectasides, Dimitrios, Fountzilas, George, Guo, Jun, Gogas, Helen, Middleton, Mark R.
Publicado 2015

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

por Lipplaa, Astrid, Fernandes, Ricardo, Marshall, Andrea, Lorigan, Paul, Dunn, Janet, Myers, Kevin A., Barker, Emily, Newton-Bishop, Julia, Middleton, Mark R., Corrie, Pippa G.
Publicado 2018

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study

por Middleton, Mark R., Dalle, Stéphane, Claveau, Joel, Mut, Pilar, Hallmeyer, Sigrun, Plantin, Patrice, Highley, Martin, Kotapati, Srividya, Le, Trong Kim, Brokaw, Jane, Abernethy, Amy P.
Publicado 2016

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

por Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Publicado 2017